| abstract |
The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombi-nant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and in-tranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The in-vention further provides a composition useful in administering rhCC10 to humans. |